AbbVie annual return on equity
2014
2015
2016
2017
2020
2021
2022
2023
2024
2025
AbbVie Return on Equity (ROE) Growth & History (ABBV)
AbbVie's return on equity was 15,367.27% for fiscal 2025.
View full AbbVie company overviewAbbVie annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 15,367.27% | +15304.75 pp |
| 2024 | 2024-12-31 | 62.52% | +27.30 pp |
| 2023 | 2023-12-31 | 35.22% | −37.25 pp |
| 2022 | 2022-12-31 | 72.48% | −8.57 pp |
| 2021 | 2021-12-31 | 81.04% | −107.21 pp |
| 2020 | 2020-12-31 | 188.25% | — |
| 2017 | 2017-12-31 | 109.09% | −29.66 pp |
| 2016 | 2016-12-31 | 138.75% | −42.16 pp |
| 2015 | 2015-12-31 | 180.90% | +123.99 pp |
| 2014 | 2014-12-31 | 56.91% | — |
AbbVie quarterly return on equity
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2025 | 2025-06-30 | 151.66% | +133.12 pp |
| Q1 2025 | 2025-03-31 | 54.20% | +39.30 pp |
| Q4 2024 | 2024-12-31 | −0.47% | −7.79 pp |
| Q3 2024 | 2024-09-30 | 24.37% | +10.12 pp |
| Q2 2024 | 2024-06-30 | 18.53% | +3.05 pp |
| Q1 2024 | 2024-03-31 | 14.91% | +13.34 pp |
| Q4 2023 | 2023-12-31 | 7.32% | −7.55 pp |
| Q3 2023 | 2023-09-30 | 14.25% | −11.52 pp |
| Q2 2023 | 2023-06-30 | 15.49% | +9.51 pp |
| Q1 2023 | 2023-03-31 | 1.57% | −26.77 pp |
| Q4 2022 | 2022-12-31 | 14.88% | −13.05 pp |
| Q3 2022 | 2022-09-30 | 25.77% | +1.43 pp |
| Q2 2022 | 2022-06-30 | 5.97% | +0.14 pp |
| Q1 2022 | 2022-03-31 | 28.34% | +1.81 pp |
| Q4 2021 | 2021-12-31 | 27.93% | +27.68 pp |
| Q3 2021 | 2021-09-30 | 24.34% | +8.94 pp |
| Q2 2021 | 2021-06-30 | 5.83% | +26.07 pp |
| Q1 2021 | 2021-03-31 | 26.53% | — |
| Q4 2020 | 2020-12-31 | 0.25% | — |
| Q3 2020 | 2020-09-30 | 15.40% | — |
| Q2 2020 | 2020-06-30 | −20.24% | — |
| Q2 2018 | 2018-06-30 | 2,228.09% | +2193.29 pp |
| Q1 2018 | 2018-03-31 | 64.35% | +28.83 pp |
| Q4 2017 | 2017-12-31 | 0.88% | −24.17 pp |
| Q3 2017 | 2017-09-30 | 25.69% | −0.70 pp |
| Q2 2017 | 2017-06-30 | 34.80% | +3.48 pp |
| Q1 2017 | 2017-03-31 | 35.52% | +3.99 pp |
| Q4 2016 | 2016-12-31 | 25.05% | −9.39 pp |
| Q3 2016 | 2016-09-30 | 26.39% | +2.49 pp |
| Q2 2016 | 2016-06-30 | 31.31% | −8.39 pp |
| Q1 2016 | 2016-03-31 | 31.53% | −34.00 pp |
| Q4 2015 | 2015-12-31 | 34.45% | — |
| Q3 2015 | 2015-09-30 | 23.90% | — |
| Q2 2015 | 2015-06-30 | 39.70% | — |
| Q1 2015 | 2015-03-31 | 65.53% | — |
AbbVie return on equity trends
Over the last five fiscal years, AbbVie's return on equity increased from 188.25% to 15,367.27%, a change of +15179.02 percentage points. The latest reported quarter, Q2 2025, shows 151.66%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...